Copyright © 2006, European Society of Cardiology
ACE inhibitors and statins for bone marrow failure following myocardial infarction?
aDepartment of Physiology, Maastricht University, CARIM, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands
bDepartment of Cardiology, University Hospital Maastricht, CARIM, P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands
* Corresponding author. Tel.: +31 43 3881200; fax: +31 43 3884166. Email address: m.post@fys.unimaas.nl
Received 6 February 2006; accepted 7 February 2006
| The first 10% of the full text of this article appears below. |
See article by Thum et al. [4] (pages 50–60) in this issue.
Since their initial description a decade ago, endothelial precursor cells (EPCs) have been intensively studied, especially in relation to vascular injury or pathology and their clinical consequences. However, there is no consensus on the precise phenotypic definition of EPCs. Nonetheless, it has been established that these EPCs contribute to neovascularization in a variety of tissues [1] and they may even play a role in tissue regeneration if they transdifferentiate and integrate into functional tissue, for instance myocardium. The latter, however, is highly controversial.
Recruitment of EPCs